Objective To investigate the effects of pioglitazone on fasting serum adiponectin and visfatin levels in patients with type 2 diabetes mellitus(T2DM).Methods A case-control and a self-controlled study were conducted in 49 patients with newly diagnosed T2DM (T2DM group) and 50 healthy subjects (normal control group).Fasting serum adiponectin and visfatin levels were compared between the two groups,and the changes in the levels were measured after treatment with pioglitazone for 12 weeks.Results Compared with normal control group,pioglitazone induced a decrease in fasting serum levels of adiponectin and an increase in levels of visfatin [(12.3±2.8)mg · L-1 vs (6.4±l.1)mg· L-1]and [(13.5±9.2)μg · L-1 vs (36.2±10.6) μg · L-1], (P＜0.01).Compared with the levels before treatment, adiponectin levels markedly increased 12 weeks after treatment with pioglitazone [(9.1 ±1.4)mg · L-1 vs (6.4±1.1)mg · L-1 , P＜0.05], but no changes in visfatin levels were observed [(34.5 ±11.4)μg · L-1 vs (36.2±10.6)μg · L-1 ,P＞0.05].Conclusion Pioglitazone can improve the decrease in serum adiponectin levels, but has no impact on the levels of serum visfatin in patients with T2DM.%目的 观察吡格列酮对2型糖尿病(T2DM)患者血清脂联素、内脂素的影响.方法 对新诊断的49例T2DM患者(T2DM组)和50例健康体检者(对照组)采用病例对照及治疗前后自身对照的方法,比较2组治疗前及T2DM组经吡格列酮治疗12周后空腹血清脂联素、内脂素的水平.结果 T2DM组治疗前与对照组相比,脂联素水平下降[(6.4±1.1)mg·L-1 vs (12.3±2.8)mg·L-1,P＜0.01],内脂素水平升高[(36.2±10.6)μg·L-1 vs (13.5±9.2)μg·L-1,P＜0.01];治疗后T2DM组与治疗前比较,脂联素明显升高[(9.1±1.4)mg·L-1 vs (6.4±1.1)mg·L-1,P＜0.05],而内脂素无明显变化[(34.5 ±11.4)μg·L-1 vs (36.2±10.6)μg·L-1,fquP＞0.05].结论 吡格列酮治疗可改善T2DM所导致的脂联素水平改变,而对内脂素水平无明显影响.
展开▼
